{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:20:16Z","timestamp":1782433216200,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"United Safety Medical Group","award":["USGN2019001"],"award-info":[{"award-number":["USGN2019001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Our study aimed to determine the association between homocysteine levels and cardiovascular disease (CVD) risk in middle-aged and elderly adults in a community in northern Taiwan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants in our study included adults aged 50 to 85\u00a0years old during community health examinations in 2019. A total of 396 people were enrolled, the ethnicity of all participants is Chinese. We divided participants according to tertiles of ln[homocysteine] level (low, middle and high groups). The CVD risk was calculated by the Framingham cardiovascular risk score (FRS). An FRS\u2009\u2265\u200920% indicated high CVD risk. Pearson correlation coefficients were calculated between homocysteine level and other cardio-metabolic risk factors while adjusting for age. Multivariate logistic regression analysis was used to determine the association of high and middle ln[homocysteine] groups with high CVD risk after adjusting age, sex, uric acid, creatinine, and body mass index (BMI). The Youden index and receiver operating characteristic (ROC) curves were performed to determine the optimized cut-off value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 396 people enrolled for analysis; 41.4% of participants were male, and the average age was 64.79 (\u00b1\u20098.76). In our study, we showed a positive correlation of homocysteine with FRS. In the logistic regression models, higher ln[homocysteine] levels was associated with higher CVD risk with a odds ratio (OR) of 2.499 and 95% confidence interval (CI) of 1.214 to 5.142 in the high homocysteine level group compared with the low homocysteine group after adjusting for traditional CVD risk factors. The area under the ROC curve was 0.667, and a ln[homocysteine] cut-off value of 2.495\u00a0\u00b5mol\/L was determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Middle-aged and elderly people with increased homocysteine levels were associated with higher FRSs in this Taiwan community. Furthermore, homocysteine was an independent risk factor for high CVD risk in this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-021-02000-x","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T06:03:50Z","timestamp":1618898630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The association between homocysteine levels and cardiovascular disease risk among middle-aged and elderly adults in Taiwan"],"prefix":"10.1186","volume":"21","author":[{"given":"Chin-Chuan","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-7833","authenticated-orcid":false,"given":"Jau-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"2000_CR1","unstructured":"Centers for Disease Control and Prevention. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2014. CDC;2015."},{"key":"2000_CR2","unstructured":"World Health Organization. World Health Organization: deaths by cause, age and sex, by world bank income group, 2000\u20132015. WHO: Geneva 2018."},{"key":"2000_CR3","first-page":"12","volume":"2","author":"NJ Pagidipati","year":"2013","unstructured":"Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;2:12.","journal-title":"Circulation"},{"key":"2000_CR4","first-page":"29","volume":"9","author":"SS Mahmood","year":"2013","unstructured":"Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2013;9:29.","journal-title":"Lancet"},{"issue":"2","key":"2000_CR5","doi-asserted-by":"publisher","first-page":"456S","DOI":"10.1093\/ajcn\/83.2.456S","volume":"83","author":"P Libby","year":"2006","unstructured":"Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutrit. 2006;83(2):456S-460S.","journal-title":"Am J Clin Nutrit"},{"key":"2000_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/01.ATV.0000174796.81443.3f","volume":"25","author":"J Nilsson","year":"2005","unstructured":"Nilsson J. CRP\u2014marker or maker of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1527\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2000_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2147\/VHRM.S29284","volume":"8","author":"J Yayan","year":"2012","unstructured":"Yayan J. Erythrocyte sedimentation rate as a marker for coronary heart disease. Vasc Health Risk Manag. 2012;8:219\u201323.","journal-title":"Vasc Health Risk Manag"},{"issue":"8","key":"2000_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14779072.2018.1497974","volume":"16","author":"SG Chrysant","year":"2018","unstructured":"Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovasc Therapy. 2018;16(8):559\u201365.","journal-title":"Exp Rev Cardiovasc Therapy"},{"key":"2000_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.biochi.2020.02.012","volume":"173","author":"B Balint","year":"2020","unstructured":"Balint B, Jepchumba VK, Gu\u00e9ant JL, Gu\u00e9ant-Rodriguez RM. Mechanisms of homocysteine-induced damage to the endothelial, medial and adventitial layers of the arterial wall. Biochimie. 2020;173:100\u20136.","journal-title":"Biochimie"},{"issue":"4","key":"2000_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/187152910793743887","volume":"10","author":"M Finch","year":"2010","unstructured":"Finch M, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Haematol Disorders Drug Targets. 2010;10(4):241\u20135.","journal-title":"Cardiovasc Haematol Disorders Drug Targets"},{"issue":"2","key":"2000_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.300.2.197","volume":"300","author":"nkle Brachial Index Collaboration","year":"2008","unstructured":"nkle Brachial Index Collaboration. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197.","journal-title":"JAMA"},{"issue":"1","key":"2000_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12325-019-01154-7","volume":"37","author":"BY Lin","year":"2020","unstructured":"Lin BY, Li P, Wu XD, Li H, Zeng ZY. The relationship between homocysteine, blood pressure variability, and left ventricular hypertrophy in patients with essential hypertension: an observational study. Advances in therapy. 2020;37(1):381\u20139.","journal-title":"Advances in therapy"},{"key":"2000_CR13","doi-asserted-by":"crossref","unstructured":"Awasthi M, Omoike OE, Paul TK, Ridner SL, Mamudu HM, An association between smoking status and homocysteine levels and whether this association is modified by sex hormones and cholesterol (2019)","DOI":"10.1016\/j.annepidem.2019.08.023"},{"issue":"9","key":"2000_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41371-019-0288-6","volume":"34","author":"H Weng","year":"2020","unstructured":"Weng H, Li Y, Fan F, Yang H, Zhou G, Sun P, Li J. The association between total homocysteine and blood pressure in two independent Chinese populations. J Hum Hyperten. 2020;34(9):657\u201365.","journal-title":"J Hum Hyperten"},{"issue":"1","key":"2000_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-016-0392-3","volume":"16","author":"M Momin","year":"2017","unstructured":"Momin M, Jia J, Fan F, Li J, Dou J, Chen D, Zhang Y. Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population. Lip Health Disease. 2017;16(1):1\u20137.","journal-title":"Lip Health Disease"},{"issue":"1","key":"2000_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.amjcard.2004.03.023","volume":"94","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D\u2019Agostino RB, Levy D. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20\u20134.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2000_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/14779072.2018.1497974","volume":"16","author":"SG Chrysant","year":"2018","unstructured":"Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Exp Rev Cardiovas Therapy. 2018;16(8):559\u201365.","journal-title":"Exp Rev Cardiovas Therapy"},{"issue":"1","key":"2000_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10545-006-0106-5","volume":"29","author":"R Castro","year":"2006","unstructured":"Castro R, Rivera I, Blom HJ, Jakobs C, De Almeida IT. Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview. J Inherited Metab Dis. 2006;29(1):3\u201320.","journal-title":"J Inherited Metab Dis"},{"issue":"12","key":"2000_CR19","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1161\/CIRCULATIONAHA.105.570127","volume":"113","author":"V Menon","year":"2006","unstructured":"Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Shlipak MG. Relationship between homocysteine and mortality in chronic kidney disease. Circulation. 2006;113(12):1572\u20137.","journal-title":"Circulation"},{"issue":"9","key":"2000_CR20","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.3390\/nu5093481","volume":"5","author":"R Obeid","year":"2013","unstructured":"Obeid R. The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. Nutrients. 2013;5(9):3481\u201395.","journal-title":"Nutrients"},{"key":"2000_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3389\/fncel.2015.00391","volume":"9","author":"E Bukharaeva","year":"2015","unstructured":"Bukharaeva E, Shakirzyanova A, Khuzakhmetova V, Sitdikova G, Giniatullin R. Homocysteine aggravates ROS-induced depression of transmitter release from motor nerve terminals: potential mechanism of peripheral impairment in motor neuron diseases associated with hyperhomocysteinemia. Front Cellular Neurosci. 2015;9:391.","journal-title":"Front Cellular Neurosci"},{"issue":"1","key":"2000_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11010-009-0270-7","volume":"335","author":"XD Ke","year":"2010","unstructured":"Ke XD, Foucault-Bertaud A, Genovesio C, Dignat-George F, Lamy E, Charpiot P. Homocysteine modulates the proteolytic potential of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cellular Biochem. 2010;335(1):203\u201310.","journal-title":"Mol Cellular Biochem"},{"issue":"5","key":"2000_CR23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/labinvest.3780275","volume":"81","author":"P Durand","year":"2001","unstructured":"Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab Investig. 2001;81(5):645\u201372.","journal-title":"Lab Investig"},{"issue":"3","key":"2000_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dsx.2016.08.026","volume":"11","author":"B Sreckovic","year":"2017","unstructured":"Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H, Mrdovic I. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndrome Clin Res Rev. 2017;11(3):179\u201382.","journal-title":"Diabetes Metab Syndrome Clin Res Rev"},{"key":"2000_CR25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fnins.2016.00538","volume":"10","author":"J Lehotsk\u00fd","year":"2016","unstructured":"Lehotsk\u00fd J, Tothov\u00e1 B, Kovalsk\u00e1 M, Dobrota D, Be\u0148ov\u00e1 A, Kalensk\u00e1 D, Kapl\u00e1n P. Role of homocysteine in the ischemic stroke and development of ischemic tolerance. Front Neurosci. 2016;10:538.","journal-title":"Front Neurosci"},{"issue":"8","key":"2000_CR26","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0003319713502253","volume":"65","author":"A Schaffer","year":"2014","unstructured":"Schaffer A, Verdoia M, Barbieri L, Aprami TM, Suryapranata H, Marino P, Luca GD. High-density lipoproteins and coronary artery disease: a single-center cohort study. Angiology. 2014;65(8):696\u2013702.","journal-title":"Angiology"},{"key":"2000_CR27","doi-asserted-by":"crossref","unstructured":"Andras A, Stansby G, Hansrani M. Homocysteine lowering interventions for peripheral arterial disease and bypass grafts. Cochrane Database Syst Rev, 2013;7","DOI":"10.1002\/14651858.CD003285.pub2"},{"issue":"2","key":"2000_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2013.02.019","volume":"228","author":"SM Krishna","year":"2013","unstructured":"Krishna SM, Dear A, Craig JM, Norman PE, Golledge J. The potential role of homocysteine mediated DNA methylation and associated epigenetic changes in abdominal aortic aneurysm formation. Atherosclerosis. 2013;228(2):295\u2013305.","journal-title":"Atherosclerosis"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02000-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02000-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T06:13:26Z","timestamp":1618899206000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02000-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2000"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02000-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-120665\/v1","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"5 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Linkou Chang Gung Memorial Hospital (No.1901150007), all participants were informed and gave their consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}